Abstracts tagged "monoclonal antibodies"

Abstract Number: 009 • 2020 Pediatric Rheumatology Symposium
Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)
Fabrizio De Benedetti¹, Paul Brogan ², Claudia Bracaglia ¹, Manuela Pardeo ¹, Giulia Marucci ¹, Emanuela Sacco ¹, Despina Eleftheriou ³, Charalampia Papadopoulou ³, Alexei Grom ⁴, Pierre Quartier ⁵, Rayfel Schneider ⁶, Philippe Jacqmin ⁷, Rikke Frederiksen ⁸, Maria Ballabio ⁹ and Cristina de Min ⁸, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Paris-Descartes University, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷MnS Modelling and Simulation, Dinant, Belgium, ⁸Swedish Orphan Biovitrum AG (Sobi), Basel, Basel-Stadt, Switzerland, ⁹Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a severe complication of rheumatic diseases and occurs most frequently in patients with sJIA. Data from animal models and from observational studies…
Abstract Number: L13 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Philip J. Mease¹, Proton Rahman ², Alice B. Gottlieb ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Xie Xu ⁶, Ramanand Subramanian ⁵, Prasheen Agarwal ⁵, Shihong Sheng ⁵, Bei Zhou ⁵, Désirée van der Heijde ⁷ and Iain McInnes ⁸, ¹Swedish Medical Center and University of Washington, Seattle, Washington, ²Memorial University of Newfoundland, Newfoundland, Canada, ³Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, ⁵Janssen Research & Development, LLC, Spring House, Pennsylvania, ⁶Janssen Research & Development, LLC, Spring House, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
Abstract Number: 532 • 2019 ACR/ARP Annual Meeting
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Hayato Hisaki ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 1410 • 2019 ACR/ARP Annual Meeting
Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis
Alberto Migliore¹, Giuseppe Pompilio ², Davide Integlia ², Joe Zhuo ³ and Evo Alemao ⁴, ¹Unit of Rheumatology Ospedale S. Pietro Fatebenefratelli, Rome, Italy, ²Isheo Srl, Rome, Italy, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb, Princeton
Background/Purpose: TNF inhibitors are a common treatment for rheumatoid arthritis (RA), but there is no best practice for when a specific TNF inhibitor stops working1.…
Abstract Number: 1523 • 2019 ACR/ARP Annual Meeting
Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Alan Menter ¹, Zoe Draelos ², Jayme Heim ³, Jeff Parno ⁴, Alan Mendelsohn⁴, Stephen Rozzo ⁴ and Christopher Griffiths ⁵, ¹Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA, Dallas, TX, ²Dermatology Consulting Services, High Point, NC, USA, High Point, NC, ³West Michigan Dermatology, Holland, MI, USA, Holland, MI, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody approved for the treatment of moderate-to-severe chronic plaque psoriasis. An inverse efficacy–body weight relationship has been…
Abstract Number: 1524 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
Alice Gottlieb ¹, Ana-Maria Orbai ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Luis R. Espinoza ⁵, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved by the FDA to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo-controlled, phase 2b…
Abstract Number: 1525 • 2019 ACR/ARP Annual Meeting
Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Christopher Ritchlin ¹, Vibeke Strand ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Arthur Kavanaugh ⁵, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tildrakizumab (TIL) is an anti–interleukin-23p19 monoclonal antibody approved by the FDA for treatment of moderate-to-severe plaque psoriasis1,2 and is under investigation for treatment of…
Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study
Wendy Cantrell ¹, Patricia Lee ², Emil Tanghetti ³, Alan Mendelsohn⁴, Jeff Parno ⁴, Stephen Rozzo ⁴ and Wilson Liao ⁵, ¹Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, ²Center for Clinical Studies, Webster, TX, USA, Webster, TX, ³Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting
Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Holly Glover ¹, Kristine Kucera ², Alan Mendelsohn³, Jeff Parno ³, Stephen Rozzo ³, Frank Ferritto ⁴ and Renata Block ⁵, ¹Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, ²North Texas Dermatology, Richardson, TX, USA, Richardson, TX, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴Polley Dermatology, Wilson, NC, USA, Wilson, NC, ⁵Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…
Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip Mease¹, Saima Chohan ², Ferran J. García Fructuoso ³, Alice Gottlieb ⁴, Richard C. Chou ⁵, Alan Mendelsohn ⁶, Rocco Ballerini ⁶ and Michael E. Luggen ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ, USA, Phoenix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁶Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁷Cincinnati Rheumatic Disease Study Group, Inc. and University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…
Abstract Number: L20 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
Thomas J. Schnitzer¹, Richard Easton², Shirley Pang³, Dennis Levinson⁴, Glenn Pixton⁵, Lars Viktrup⁶, Isabelle Davignon⁷, Mark T. Brown⁷, Kenneth M. Verburg⁷ and Christine R. West⁷, ¹Northwestern University, Chicago, IL, ²Michigan Orthopaedic & Spine Surgeons, Rochester Hills, MI, ³St. Jude Medical Center, Fullerton, CA, ⁴Chicago Clinical Research Institute, Chicago, IL, ⁵Pfizer, Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized mAb that blocks nerve growth factor (NGF) and is in clinical development for chronic pain treatment. Tanezumab administered intravenously has…
Abstract Number: 1574 • 2018 ACR/ARHP Annual Meeting
Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum
Kristi A. Koelsch^1,2,3, Joshua Cavett^3,4, Kenneth Smith³, Jacen Maier-Moore⁵, Astrid Rasmussen³, David M. Lewis⁶, Lida Radfar⁷, Biji T. Kurien^2,4,8, Judith A. James^3,9, Kathy L. Sivils¹⁰, A. Darise Farris¹¹ and R. Hal Scofield^2,11,12, ¹Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Okalahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, ⁶Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁷Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁸Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma, OK, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: There is evidence for B cell involvement in the pathogenesis of Sjögren’s syndrome by the presence of autoantigen-specific B cells. Autoantibodies toward Ro/SSA and…
Abstract Number: 2525 • 2018 ACR/ARHP Annual Meeting
Correlation Analysis between Sirukumab Exposure and Selected Safety Events Following Subcutaneous Administration Using Pooled Phase 3 Data in Rheumatoid Arthritis
Yan Xu¹, Yanli Zhuang¹, Chuanpu Hu¹, Benjamin Hsu², Zhenhua Xu¹, Amarnath Sharma¹ and Honghui Zhou¹, ¹Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, ²Immunology Clinical Development, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: To characterize the exposure-response (ER) relationship between systemic exposure to sirukumab (an anti- interleukin-6 [IL-6] human monoclonal antibody) and the occurrence of selected safety…
Abstract Number: 2626 • 2018 ACR/ARHP Annual Meeting
Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
Bernard Combe¹, Paul Emery², Annelies Boonen³, Soyi Liu Leage⁴, Christophe Sapin⁴, Natalia Bello⁵ and Maxime Dougados⁶, ¹CHU, Montpellier University, Montpelier, France, Montpellier, France, ²Leeds Musculoskeletal Biomedical Research Unit, LTHT Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ³Division of Rheumatology, Maastricht University, School for Public Health and Primary Care, Maastricht University Medical Centre, The Netherlands, Maastricht, Netherlands, ⁴Lilly France, Neuilly sur Seine Cedex, France, Neuilly sur Seine Cedex, France, ⁵Eli Lilly and Company (Spain), Alcobendas, Spain, Alcobendas, Spain, ⁶Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France
Background/Purpose: It is important to understand the association between early changes in inflammatory biomarkers and treatment response at later times after initiation of a biologic…
Abstract Number: 1111 • 2018 ACR/ARHP Annual Meeting
CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis
Clarissa Corinaldesi¹, Yasser M El-Sherbiny², Gemma Migneco³, Rebecca Ross¹, Steve Holmes⁴, Clive McKimmie⁵ and Francesco Del Galdo¹, ¹Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, ⁴Capella Biosciences, LTD, London, United Kingdom, ⁵Virus Host Interactions Team, Section of Infection and Immunity, University of Leeds, Leeds, United Kingdom
Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].